Back to top
more

Dentsply Sirona (XRAY)

(Delayed Data from NSDQ)

$14.05 USD

14.05
4,310,210

-0.26 (-1.82%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $14.04 -0.01 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (59 out of 246)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

What's in Store for DENTSPLY (XRAY) This Earnings Season?

by Zacks Equity Research

DENTSPLY's (XRAY) CAD/CAM unit is likely to drive the top line in Q1. Product innovations and strong R&D prospects are also likely to drive growth.

    Zacks Equity Research

    Henry Schein Ties Up With Internet Brands to Boost Dental Arm

    by Zacks Equity Research

    Henry Schein (HSIC) banks on part of its strategic plan, digital dentistry. In this regard, its latest joint venture with Internet Brands buoys optimism.

      Zacks Equity Research

      New Strong Sell Stocks for April 9th

      by Zacks Equity Research

      Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

        Zacks Equity Research

        DENTSPLY to Acquire OraMetrix, Boost CAD-CAM Dental Unit

        by Zacks Equity Research

        The acquisition of OraMetrix is likely to bolster DENTSPLY's (XRAY) dental business.

          Gargi Seth headshot

          Dental Implant & Prosthetic Boom Puts Spotlight on 3 Stocks

          by Gargi Seth

          The dental market has outperformed the broader market in last ten years on the back of demand from both teenagers and adults.

            Zacks Equity Research

            Here's Why You Should Steer Clear of DENTSPLY (XRAY) for Now

            by Zacks Equity Research

            DENTSPLY SIRONA (XRAY) faces foreign exchange woes and chances of margin decline in the quarters ahead.

              Zacks Equity Research

              New Strong Sell Stocks for March 19th

              by Zacks Equity Research

              Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

                Zacks Equity Research

                DENTSPLY (XRAY) Earnings and Revenues Beat Estimates in Q4

                by Zacks Equity Research

                Strong performance at Dental & Healthcare Consumables segment drives DENTSPLY's (XRAY) Q4 sales.

                  Zacks Equity Research

                  Patterson Companies (PDCO) Q3 Earnings: What's in Store?

                  by Zacks Equity Research

                  Diverse product portfolio and strong veterinary business prospects to drive Patterson Companies (PDCO) in Q3. However, sluggishness in the Dental-Supply segment is a woe.

                    Zacks Equity Research

                    Can Geographical Sales Aid DENTSPLY's (XRAY) Q4 Earnings?

                    by Zacks Equity Research

                    DENTSPLY (XRAY) anticipates lower regional sales to dent results in Q4. The company continues to focus on operational excellence.

                      Zacks Equity Research

                      Patterson Companies' (PDCO) Dental Segment Shows Weakness

                      by Zacks Equity Research

                      Changing healthcare environment in the United States, unfavorable price movements and competitive dental products industry are posing challenges for Patterson Companies, Inc. (PDCO).

                        Zacks Equity Research

                        Align Teams Up with Exocad to Expand in Digital Scanning

                        by Zacks Equity Research

                        Align's (ALGN) collaboration with CAD/CAM software provider, Exocad GmbH, is likely to integrate the Chairside CAD software into Align's iTero Element intraoral scanner.

                          Zacks Equity Research

                          DENTSPLY SIRONA Strong on Deal Renewals, Forex Woes Stay

                          by Zacks Equity Research

                          DENTSPLY SIRONA's (XRAY) renewed distribution deal will help the company gain market traction. However, forex woes remain a concern.

                            Zacks Equity Research

                            Align Technology-Glidewell Dental Deal to Boost iTero Uptake

                            by Zacks Equity Research

                            Align Technology (ALGN) progresses with deals to boost the Scanners and Services segment.

                              Zacks Equity Research

                              DENTSPLY (XRAY) Earnings and Revenues Beat Estimates in Q3

                              by Zacks Equity Research

                              DENTSPLY SIRONA (XRAY) reported third-quarter 2017 adjusted earnings per share (EPS) of 70 cents, beating the Zacks Consensus Estimate by 4 cents.

                                Zacks Equity Research

                                DENTSPLY (XRAY) Q3 Earnings Beat Estimates, Sales Rise Y/Y

                                by Zacks Equity Research

                                DENTSPLY reported adjusted earnings of 70 cents per share, which came above the Zacks Consensus Estimate by 4 cents and was higher than earnings of 66 cents in the year-ago quarter.

                                  Zacks Equity Research

                                  Can DENTSPLY (XRAY) Deliver a Beat This Earnings Season?

                                  by Zacks Equity Research

                                  In the third quarter, DENTSPLY (XRAY) is expected to witness strong growth in revenues, particularly in the dental consumables and laboratories segment.

                                    Zacks Equity Research

                                    DENTSPLY SIRONA Strong on Deal Renewals, Forex Woes Stay

                                    by Zacks Equity Research

                                    DENTSPLY SIRONA's (XRAY) renewed distribution deal will aid the company to gain market traction. However, forex woes remain a concern.

                                      Zacks Equity Research

                                      Top MedTech Stocks Safe from Graham-Cassidy Repeal Bill

                                      by Zacks Equity Research

                                      The investment climate for medical device majors has become increasingly volatile due to political potshots in Capitol Hill, for and against Obamacare.

                                        Zacks Equity Research

                                        New Strong Sell Stocks for September 12th

                                        by Zacks Equity Research

                                        Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

                                          Zacks Equity Research

                                          New Strong Sell Stocks for August 16th

                                          by Zacks Equity Research

                                          Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

                                            Zacks Equity Research

                                            DENTSPLY (XRAY) Earnings and Revenues Miss Estimates in Q2

                                            by Zacks Equity Research

                                            DENTSPLY SIRONA (XRAY) reported lukewarm second-quarter results owing to inventory reduction related to a change in the distribution strategy in North America and lower equipment sales to end users.

                                              Zacks Equity Research

                                              DENTSPLY (XRAY) Q2 Earnings Miss Estimates, Sales Fall Y/Y

                                              by Zacks Equity Research

                                              DENTSPLY reported adjusted earnings of 65 cents per share, which missed the Zacks Consensus Estimate by a penny and was lower than earnings of 76 cents in the year-ago quarter.

                                                Zacks Equity Research

                                                4 Medical Product Stocks Likely to Top Q2 Earnings Estimates

                                                by Zacks Equity Research

                                                There are some powerful long-term tailwinds in the medical space.

                                                  Zacks Equity Research

                                                  Why DENTSPLY (XRAY) Might Surprise This Earnings Season

                                                  by Zacks Equity Research

                                                  DENTSPLY (XRAY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.